IgA nephropathy (IgAN), the most prevalent primary glomerulonephritis worldwide, carries a
considerable lifetime risk of kidney failure. Clinical manifestations of IgAN vary from …

IgA nephropathy (IgAN) is the most common glomerular disease in the world. However, the
approach to treatment remains controversial. There has been an explosion of clinical trials …

Background A proliferation-inducing ligand (APRIL) is implicated in the pathogenesis of IgA
nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and …

Background IgA nephropathy can progress to kidney failure, and risk assessment soon after
diagnosis has advantages both for clinical management and the development of new …

Background IgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …

Background Sparsentan, a novel, non-immunosuppressive, single-molecule, dual
endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus …

The therapeutic potential of a novel, targeted-release formulation of oral budesonide
(Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase …

Targeting the alternative complement pathway is an attractive therapeutic strategy given its
role in the pathogenesis of immunoglobulin A nephropathy (IgAN). Iptacopan (LNP023) is …

Importance The role of mycophenolate mofetil (MMF) in management of immunoglobulin A
nephropathy (IgAN) remains highly controversial. Objective To evaluate the efficacy and …

Introduction Targeting the alternative complement pathway (AP) is an attractive therapeutic
strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology …